Can You Test for LSD? The Science of Detection

LSD can be detected in urine, blood, saliva, and hair, but it is one of the hardest recreational drugs to catch on a test. The doses are extraordinarily small, the body breaks it down quickly, and most standard workplace drug panels do not even look for it. When specialized testing is used, the window for a positive result is narrow, and the analytical methods involved are far more sensitive and expensive than those used for common drugs. All of this makes LSD detection a genuinely interesting problem in forensic and clinical toxicology.

Why LSD Is So Hard to Detect

A typical dose of LSD is measured in micrograms, not milligrams. Where a single dose of most other drugs puts milligrams or even grams of a substance into the body, an active dose of LSD might be 100 micrograms, roughly one ten-thousandth of a gram. That tiny amount gets distributed through the whole body and then broken down rapidly. The plasma half-life of LSD is about three and a half hours, meaning that half the drug is gone from the blood roughly every three to four hours after the peak.

This combination of minuscule dose and fast metabolism means that by the time someone provides a sample, there may be almost nothing left to find. A recent review of analytical challenges in LSD detection described the difficulty as stemming directly from these factors: low dosage, rapid metabolism, and the structural similarities between LSD and newer synthetic analogs that complicate identification even further.

Standard Workplace Drug Tests Usually Skip LSD

The most common workplace drug screening in the United States is the five-panel urine test, which checks for amphetamines, cannabinoids (marijuana), cocaine, opiates, and phencyclidine (PCP). LSD is not on this panel. Even expanded panels with seven, ten, or twelve targets rarely include LSD, because the testing is expensive and the prevalence of LSD use in the workplace population is low compared with other drugs. Military drug testing programs, for instance, have historically focused on cannabis, amphetamines, opiates, and cocaine.

If you are wondering whether a routine pre-employment or random workplace drug test will flag LSD use, the answer is almost certainly no. LSD testing requires a deliberate request and specialized laboratory methods. It is more commonly ordered in forensic investigations, clinical poisoning cases, or specific situations where LSD use is suspected.

Urine Testing and the Key Metabolite

When LSD testing is performed, urine is the most commonly used sample. But the approach is not as simple as looking for LSD itself. The body converts most of the LSD it absorbs into breakdown products, and the most important of these is a metabolite called 2-oxo-3-hydroxy-LSD (often abbreviated O-H-LSD). This metabolite turns out to be far more useful to labs than the parent drug, because it shows up in urine at concentrations roughly 16 to 43 times higher than LSD itself.

Early research on this metabolite confirmed the pattern. In urine samples that contained LSD at concentrations between roughly 560 and 7,000 picograms per milliliter, O-H-LSD showed up at concentrations between about 8,000 and 28,500 picograms per milliliter, anywhere from 4 to 41 times higher.

⁴

Because O-H-LSD is present in higher amounts and remains detectable for a longer window after ingestion than LSD itself, modern laboratories have made it the primary target for confirming LSD use in urine.

⁵

The detection window for LSD in urine is still relatively short compared with many other drugs. Depending on the dose and the sensitivity of the test, LSD and O-H-LSD can generally be found in urine for about two to four days after use. Contrast that with cannabis metabolites, which can linger for weeks in heavy users, and you can see why catching LSD use in a routine screening is so uncommon.

The Problem With Immunoassay Screening

When labs do screen for LSD, the first step is usually an immunoassay, a quick, inexpensive antibody-based test. These work well as a first pass for most drugs, but they are notorious for producing false positives with LSD. The antibodies used in the test can cross-react with other substances that have nothing to do with LSD.

A well-documented example involves ambroxol, a common cough medication used widely in Europe and other regions. In one study, 12 patients in an intensive care unit produced unexpected positive results for LSD on a routine immunoassay screen. None of the results held up when the samples were tested with more precise methods, and every one of those patients had been taking ambroxol for respiratory infections.

⁶

A broader review of false-positive immunoassay results found cross-reactivity problems across most drug classes, including LSD, and reinforced the widely accepted principle that immunoassay results are considered presumptive until confirmed by a second, independent method.

⁷

In practice, this means a positive immunoassay result for LSD should never be treated as definitive on its own. It always needs follow-up testing.

Confirmatory Testing With Mass Spectrometry

The gold standard for confirming LSD in any biological sample is liquid chromatography coupled with tandem mass spectrometry, commonly referred to as LC-MS/MS. This technique physically separates the molecules in a sample and then identifies them by their unique molecular weight and fragmentation pattern. It is specific enough to distinguish LSD from its metabolites, from structurally similar compounds, and from substances that fool immunoassays.

In clinical research settings, validated LC-MS/MS methods have been developed to quantify not just LSD itself but also iso-LSD, O-H-LSD, and nor-LSD simultaneously in plasma samples.

⁸

These methods can detect LSD at concentrations measured in single-digit picograms per milliliter, which is an astonishing level of sensitivity. The trade-off is that LC-MS/MS equipment is expensive, the analysis takes longer than an immunoassay, and the technique requires trained analysts. This is why it is reserved for confirmation rather than used as a first-line screen.

Blood and Plasma Detection

LSD can be measured in blood, but the window is even shorter than in urine. After a single oral dose, plasma concentrations peak within a couple of hours, then decline following a predictable curve. With a half-life of about 3.6 hours, plasma levels drop below detection limits for most methods within 12 to 16 hours, though in some individuals a slower decline has been observed between 12 and 24 hours after dosing.

Blood testing for LSD is therefore most useful in acute settings, such as emergency departments where someone has just been brought in, or in forensic cases where timing is critical. If the sample is collected more than a day after use, blood is unlikely to yield a positive result.

Oral Fluid as a Testing Matrix

Saliva testing for LSD is an area of growing interest, partly because collecting an oral fluid sample is non-invasive and can be observed directly, reducing the risk of sample tampering. Researchers have developed LC-MS/MS methods for oral fluid that achieve limits of quantification as low as 0.01 nanograms per milliliter for both LSD and O-H-LSD.

⁹

When this method was applied to oral fluid samples from people who had taken LSD, the drug was detected in every sample tested, with concentrations ranging from 0.02 to 175 nanograms per milliliter. The metabolite O-H-LSD was also found in about half of the samples. The wide concentration range reflects both dose variation and the timing of collection relative to dosing. Oral fluid testing has practical advantages for roadside testing or supervised collection scenarios, but it is not yet standard in most clinical or workplace contexts.

Hair Testing for LSD

Hair analysis offers the theoretical advantage of a much longer detection window, potentially months, since drugs are incorporated into growing hair and remain there. For LSD, however, hair testing pushes current technology to its limits. The concentrations found in hair are vanishingly small, measured in single-digit picograms per milligram of hair.

A study analyzing hair from 18 known LSD users found LSD concentrations in the first three centimeters of hair (closest to the scalp, representing roughly the most recent three months of growth) ranging from below the limit of quantification up to 4.0 picograms per milligram, with a median of 1.5 picograms per milligram. Concentrations dropped further in older hair segments.

¹⁰

The evidence on hair testing for LSD remains thin and the interpretation of results is fraught with uncertainty. A review of the field noted that published data on LSD concentrations in hair comes from very few cases, and that a negative hair result does not rule out LSD use. Positive results are equally hard to interpret: distinguishing a single use from repeated use based on hair concentrations is essentially impossible with current data. Contamination of pubic hair by urine (which contains higher LSD concentrations) further complicates matters.

¹¹

Sample Handling Can Make or Break a Result

LSD is sensitive to light, heat, and improper storage in ways that can destroy evidence before it reaches the lab. Research on LSD stability in urine showed that samples stored at room temperature in the dark retained their concentration for up to four weeks without significant loss. But at body temperature (37°C), about 30% of the LSD was gone after four weeks, and at 45°C the loss climbed to 40%.

¹²

Light exposure proved even more damaging. LSD in transparent containers degraded significantly depending on how close the light source was, the wavelength of the light, and the duration of exposure. Samples stored in amber glass or opaque containers were protected. This matters in real-world settings: a urine sample left in a clear cup near a window, or transported without refrigeration, could test negative even though LSD was originally present. Proper chain-of-custody handling with dark containers and cool storage is not just a procedural formality for LSD testing; it is essential to getting an accurate result.

Novel LSD Analogs and Prodrugs

The rise of designer lysergamides has added another layer of complexity to LSD detection. Substances like 1P-LSD, ALD-52, and 1B-LSD have entered recreational drug markets, often sold in legal gray areas. These compounds function as prodrugs: the body strips off the added chemical group and converts them into LSD itself. Lab studies have confirmed that all three of these prodrugs undergo deacylation to produce LSD in the body.

¹³

This creates an interesting situation for drug testing. In a case involving 1P-LSD use, analysis of the person’s urine and blood found LSD at measurable levels but no detectable 1P-LSD at all, suggesting that the prodrug was completely converted to LSD in the body before the samples were collected. The researchers also found that even in stored samples, 1P-LSD could spontaneously convert to LSD at room temperature, with up to 21% conversion in serum. This means the parent compound is unstable enough that it may not survive sample collection and storage, even without being metabolized.

¹⁴

The practical upshot: if someone uses 1P-LSD, a standard LSD test will likely come back positive for LSD, because that is what the body turns it into. But the test cannot tell you which prodrug was originally taken. For forensic purposes, this ambiguity matters. For a simple yes-or-no question about LSD-type drug exposure, it may not.

Your Genetics Affect How Long LSD Lingers

Not everyone metabolizes LSD at the same rate, and the variation is partly genetic. Several liver enzymes are involved in breaking LSD down, with CYP2D6, CYP3A4, CYP2E1, and others each playing a role in producing the major metabolites nor-LSD and O-H-LSD.

¹⁵

The CYP2D6 enzyme is particularly interesting because it is highly variable across the population. Some people carry genetic variants that make this enzyme non-functional. A pooled analysis of clinical trial data found that individuals with non-functional CYP2D6 had higher overall LSD exposure in their blood, reflected in larger area-under-the-curve values, and longer half-lives compared with people whose CYP2D6 worked normally.

¹⁶

In plain terms, if you happen to be a “poor metabolizer” for CYP2D6 (estimated at around 5-10% of people of European descent), LSD stays in your system longer and hits harder at the same dose. For testing purposes, this means the detection window is not one-size-fits-all. Someone who metabolizes LSD slowly might test positive for a longer period than someone who clears it quickly. Drug interactions can also shift the equation: taking a medication that induces or inhibits the relevant enzymes could speed up or slow down LSD clearance.

Can Microdoses Be Detected?

The microdosing trend, in which people take very small amounts of LSD (typically around 10 to 25 micrograms, roughly a tenth of a standard recreational dose), raises the question of whether such tiny amounts can be picked up by testing. In a controlled study using doses of 6.5, 13, and 26 micrograms, researchers were able to measure dose-related subjective effects even at the lowest level.

¹⁷

Whether a microdose produces enough LSD and metabolites in urine or blood to cross the detection threshold of a lab test depends on the sensitivity of the method, the timing of sample collection, and the individual’s metabolism. With highly sensitive LC-MS/MS methods capable of detecting LSD at concentrations below 10 picograms per milliliter, detection is plausible even after microdoses, but the window shrinks dramatically. A microdose taken in the morning might be undetectable in urine by the next day. The smaller the dose, the faster it drops below the threshold, and the more everything depends on exactly when the sample is collected.

Field Testing and Presumptive Identification

Outside the laboratory, the options for identifying LSD are limited. Color spot tests, such as the Ehrlich reagent, can provide a presumptive indication that a substance contains an indole ring (a structural feature shared by LSD and other tryptamines), but these tests tell you very little. They cannot distinguish LSD from other lysergamides, from psilocybin, or from various research chemicals. A review of chemical spot tests noted that many of the reactions involved are poorly understood and that these methods face growing challenges as new psychoactive substances proliferate.

¹⁸

More sophisticated portable techniques like Fourier-transform infrared spectroscopy (FTIR) are used in some harm-reduction settings for drug checking, but even these struggle with LSD. Because LSD is active at such low concentrations and is typically found on blotter paper or in dilute solution, the amount of actual drug present can fall below the instrument’s detection limit.

¹⁹

Postmortem Detection and Brain Tissue

In death investigations where LSD involvement is suspected, detection becomes even more challenging because the drug continues to degrade after death. One approach that has shown promise is testing brain tissue rather than relying solely on blood. In a case series of three deaths, LSD was measured in brain tissue at concentrations ranging from 0.34 to 10.8 micrograms per kilogram, and these brain concentrations were consistently higher than those found in peripheral blood.

²⁰

This makes sense pharmacologically, since LSD crosses into the brain to exert its effects, and the drug may be somewhat more stable there than in circulating blood. For forensic pathologists, the lesson is that a negative blood result does not necessarily mean LSD was absent. Checking brain tissue can catch cases that peripheral blood samples miss, though this obviously requires autopsy and is not applicable to living subjects.